Peter Bias

1.3k total citations
44 papers, 1.0k citations indexed

About

Peter Bias is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Peter Bias has authored 44 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 19 papers in Genetics and 9 papers in Hematology. Recurrent topics in Peter Bias's work include Neutropenia and Cancer Infections (21 papers), Blood disorders and treatments (14 papers) and Erythropoietin and Anemia Treatment (5 papers). Peter Bias is often cited by papers focused on Neutropenia and Cancer Infections (21 papers), Blood disorders and treatments (14 papers) and Erythropoietin and Anemia Treatment (5 papers). Peter Bias collaborates with scholars based in Germany, Russia and Ukraine. Peter Bias's co-authors include Anton Buchner, Stefan Laufer, Igor Bondarenko, Oleg Gladkov, Christoph Behrens, Waldemar Kuczyński, T. Strowitzki, Johanne Martel‐Pelletier, D. Choquette and F. Abram and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Annals of Oncology.

In The Last Decade

Peter Bias

43 papers receiving 963 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Peter Bias 337 328 224 168 142 44 1.0k
Claudia A. Salinas 256 0.8× 235 0.7× 60 0.3× 149 0.9× 61 0.4× 29 1.4k
Wanlong Tan 72 0.2× 307 0.9× 207 0.9× 185 1.1× 34 0.2× 91 1.5k
Tzeon‐Jye Chiou 65 0.2× 254 0.8× 97 0.4× 71 0.4× 35 0.2× 66 958
Salvatore Mancuso 170 0.5× 266 0.8× 79 0.4× 47 0.3× 35 0.2× 31 1.2k
R S Amos 89 0.3× 85 0.3× 98 0.4× 675 4.0× 180 1.3× 34 1.3k
Marie‐Hélène Schlageter 52 0.2× 421 1.3× 113 0.5× 101 0.6× 16 0.1× 39 1.4k
Noémie Saut 558 1.7× 54 0.2× 75 0.3× 34 0.2× 151 1.1× 46 2.0k
Jianhui Zhang 55 0.2× 333 1.0× 73 0.3× 115 0.7× 13 0.1× 83 1.1k
R.J. Pegoraro 207 0.6× 482 1.5× 90 0.4× 66 0.4× 9 0.1× 52 1.4k
Torben Stamm Mikkelsen 93 0.3× 388 1.2× 336 1.5× 58 0.3× 39 0.3× 37 1.1k

Countries citing papers authored by Peter Bias

Since Specialization
Citations

This map shows the geographic impact of Peter Bias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Bias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Bias more than expected).

Fields of papers citing papers by Peter Bias

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Bias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Bias. The network helps show where Peter Bias may publish in the future.

Co-authorship network of co-authors of Peter Bias

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Bias. A scholar is included among the top collaborators of Peter Bias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Bias. Peter Bias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schiestl, Martin, et al.. (2020). The Path Towards a Tailored Clinical Biosimilar Development. BioDrugs. 34(3). 297–306. 41 indexed citations
2.
3.
Volovăț, Constantin, Igor Bondarenko, Oleg Gladkov, et al.. (2016). Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. Supportive Care in Cancer. 24(12). 4913–4920. 7 indexed citations
4.
5.
Pettengell, Ruth, et al.. (2016). Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. Supportive Care in Cancer. 24(6). 2677–2684. 5 indexed citations
6.
7.
Volovăț, Constantin, Igor Bondarenko, Oleg Gladkov, et al.. (2015). Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. SpringerPlus. 4(1). 316–316. 17 indexed citations
8.
9.
Gladkov, Oleg, Vladimir Moiseyenko, Igor Bondarenko, et al.. (2015). Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Medical Oncology. 32(6). 623–623. 10 indexed citations
10.
11.
Buchner, Anton, et al.. (2014). A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. Breast Cancer Research and Treatment. 148(1). 107–116. 25 indexed citations
12.
Volovăț, Constantin, Oleg Gladkov, Igor Bondarenko, et al.. (2013). Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy. Clinical Breast Cancer. 14(2). 101–108. 19 indexed citations
13.
14.
Tjulandin, Sergei, et al.. (2010). Epoetin Theta in Anaemic Cancer Patients Receiving Platinum‐Based Chemotherapy: A Randomised Controlled Trial. PubMed. 3(3). 45–53. 18 indexed citations
15.
16.
17.
Martel‐Pelletier, Johanne, Peter Bias, Stefan Laufer, et al.. (2008). Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Annals of the Rheumatic Diseases. 68(6). 938–947. 134 indexed citations
18.
Ahsen, Nicolas von, Victor W. Armstrong, Christoph Behrens, et al.. (2005). Association of Inosine Triphosphatase 94C>A and Thiopurine S-Methyltransferase Deficiency with Adverse Events and Study Drop-Outs under Azathioprine Therapy in a Prospective Crohn Disease Study. Clinical Chemistry. 51(12). 2282–2288. 75 indexed citations
19.
20.
Reginster, Jean‐Yves, Peter Bias, & Anton Buchner. (2002). First clinical results of licofelone (ml3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis. Annals of the Rheumatic Diseases. 61. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia A. Salinas Breakdown of academic impact, for papers by Wanlong Tan Breakdown of academic impact, for papers by Tzeon‐Jye Chiou Breakdown of academic impact, for papers by Salvatore Mancuso Breakdown of academic impact, for papers by R S Amos Breakdown of academic impact, for papers by Marie‐Hélène Schlageter Breakdown of academic impact, for papers by Noémie Saut Breakdown of academic impact, for papers by Jianhui Zhang Breakdown of academic impact, for papers by R.J. Pegoraro Breakdown of academic impact, for papers by Torben Stamm Mikkelsen
Rankless by CCL
2026